SI20747A - Nekristalen cefuroksim aksetilni trden dispergator, postopek za njegovo pripravo in njegovi preparati za oralno uporabo - Google Patents

Nekristalen cefuroksim aksetilni trden dispergator, postopek za njegovo pripravo in njegovi preparati za oralno uporabo Download PDF

Info

Publication number
SI20747A
SI20747A SI200020034A SI200020034A SI20747A SI 20747 A SI20747 A SI 20747A SI 200020034 A SI200020034 A SI 200020034A SI 200020034 A SI200020034 A SI 200020034A SI 20747 A SI20747 A SI 20747A
Authority
SI
Slovenia
Prior art keywords
cefuroxime axetil
water
cefuroxime
crystalline solid
dispersant
Prior art date
Application number
SI200020034A
Other languages
English (en)
Slovenian (sl)
Inventor
Hee Chui Chang
Jong Soo Woo
Original Assignee
Hanmi Pharm. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm. Co., Ltd. filed Critical Hanmi Pharm. Co., Ltd.
Publication of SI20747A publication Critical patent/SI20747A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200020034A 1999-08-04 2000-07-25 Nekristalen cefuroksim aksetilni trden dispergator, postopek za njegovo pripravo in njegovi preparati za oralno uporabo SI20747A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019990031989A KR100342943B1 (ko) 1999-08-04 1999-08-04 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
PCT/KR2000/000799 WO2001010410A1 (en) 1999-08-04 2000-07-25 Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof

Publications (1)

Publication Number Publication Date
SI20747A true SI20747A (sl) 2002-06-30

Family

ID=19606197

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200020034A SI20747A (sl) 1999-08-04 2000-07-25 Nekristalen cefuroksim aksetilni trden dispergator, postopek za njegovo pripravo in njegovi preparati za oralno uporabo

Country Status (19)

Country Link
US (1) US6107290A (ru)
EP (1) EP1080721B1 (ru)
JP (1) JP3479244B2 (ru)
KR (1) KR100342943B1 (ru)
CN (1) CN1189161C (ru)
AT (1) ATE257010T1 (ru)
AU (1) AU769451B2 (ru)
CA (1) CA2378267A1 (ru)
CZ (1) CZ2002372A3 (ru)
DE (1) DE69913958T2 (ru)
ES (1) ES2212438T3 (ru)
HU (1) HUP0202192A3 (ru)
MX (1) MXPA02001116A (ru)
NZ (1) NZ516760A (ru)
RU (1) RU2215521C1 (ru)
SI (1) SI20747A (ru)
TR (1) TR200200287T2 (ru)
WO (1) WO2001010410A1 (ru)
YU (1) YU7502A (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
IN191496B (ru) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
KR100362230B1 (ko) * 2000-04-21 2002-11-23 주식회사 대웅제약 저융점 무정형 세푸록심 악세틸의 제조방법
AU2001230490A1 (en) * 2000-12-01 2002-06-11 Arun Shriniwas Gosavi Pharmaceutical formulation
US6779246B2 (en) * 2001-04-23 2004-08-24 Appleton Papers Inc. Method and system for forming RF reflective pathways
US6892441B2 (en) * 2001-04-23 2005-05-17 Appleton Papers Inc. Method for forming electrically conductive pathways
NZ529490A (en) * 2001-06-22 2005-08-26 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug
ES2305434T3 (es) 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
TW200403075A (en) * 2002-05-29 2004-03-01 Akzo Nobel Nv Progestagenic dosage units
KR100523082B1 (ko) * 2002-09-11 2005-10-20 (주)다산메디켐 쓴 맛이 은폐된 세푸록심악세틸 제제의 제약조성물 및 그의 제조방법
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
WO2005011635A2 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US20070053973A1 (en) * 2003-10-08 2007-03-08 Shigeru Chikase Amorphous antibiotic composition comprising cefditoren pivoxil
KR100801589B1 (ko) 2004-01-09 2008-02-05 한미약품 주식회사 세푸록심 악세틸 과립 및 이의 제조방법
JP2007517864A (ja) * 2004-01-09 2007-07-05 ハンミ ファーム． シーオー．， エルティーディー． セフロキシムアキセチル顆粒及びこの製造方法
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
JP5893461B2 (ja) 2011-04-07 2016-03-23 日産自動車株式会社 位置検出装置および位置検出方法
HUE051406T2 (hu) 2012-11-14 2021-03-01 Grace W R & Co Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók
TWI586379B (zh) * 2015-06-29 2017-06-11 永信藥品工業股份有限公司 一種製作難溶藥物固體劑型的方法
CN116284050B (zh) * 2022-12-19 2024-04-12 华北制药河北华民药业有限责任公司 一种高效率结晶型头孢呋辛酯转无定型粉体的方法及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
IN186539B (ru) * 1997-09-29 2001-09-29 Ranbaxy Lab Ltd
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Also Published As

Publication number Publication date
JP2001048777A (ja) 2001-02-20
EP1080721A2 (en) 2001-03-07
ES2212438T3 (es) 2004-07-16
CN1189161C (zh) 2005-02-16
CA2378267A1 (en) 2001-02-15
DE69913958T2 (de) 2004-06-09
MXPA02001116A (es) 2002-08-20
AU5855100A (en) 2001-03-05
CN1367683A (zh) 2002-09-04
US6107290A (en) 2000-08-22
KR20010016826A (ko) 2001-03-05
TR200200287T2 (tr) 2002-07-22
HUP0202192A3 (en) 2004-04-28
KR100342943B1 (ko) 2002-07-02
AU769451B2 (en) 2004-01-29
EP1080721A3 (en) 2001-05-02
JP3479244B2 (ja) 2003-12-15
NZ516760A (en) 2004-01-30
RU2215521C1 (ru) 2003-11-10
DE69913958D1 (de) 2004-02-05
CZ2002372A3 (cs) 2002-06-12
YU7502A (sh) 2004-09-03
EP1080721B1 (en) 2004-01-02
WO2001010410A1 (en) 2001-02-15
HUP0202192A2 (en) 2002-10-28
ATE257010T1 (de) 2004-01-15

Similar Documents

Publication Publication Date Title
SI20747A (sl) Nekristalen cefuroksim aksetilni trden dispergator, postopek za njegovo pripravo in njegovi preparati za oralno uporabo
US4404183A (en) Sustained release pharmaceutical composition of solid medical material
ES2376238T3 (es) Composiciones de liberación modificada comprendiendo tacrolimus.
BRPI0414000B1 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
JPH05246844A (ja) ＨＭＧ−ＣｏＡリダクターゼ禁止剤化合物を含んでなる安定化された製薬学的組成物
MXPA05005667A (es) Dispersiones solidas que comprenden un farmaco higroscopico y/o delicuescente.
EP1952807A1 (en) Sirolimus formulation
JP2004043506A (ja) ガバペンチン含有固形製剤の製造方法
WO2013009142A2 (en) Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same
JP2008524317A (ja) 腸溶コーティングされたアジスロマイシン多粒子
TW201919621A (zh) 醫藥製劑
JP7322475B2 (ja) アジルサルタンを含有する錠剤
US20110097414A1 (en) Pharmaceutical compositions comprising adsorbate of fenofibrate
SI8710406A (en) Sustained release tablets on the basis of high molecular weight hydroxypropylmethylcellulose and a process for their manufacture
US20110311625A1 (en) Solid dosage forms of fenofibrate
US8062664B2 (en) Process for preparing formulations of lipid-regulating drugs
KR20190130411A (ko) 아픽사반 약제학적 제제 및 그의 제조방법
KR102601617B1 (ko) 비-뉴클레오시드 역전사 효소 억제제의 조성물
WO2013169523A1 (en) Solubility enhanced compositions
JP2022545822A (ja) チダミド医薬組成物、その調製方法及びその適用
WO2004105728A2 (en) Solid dispersions of cefpodoxime proxetil and processes for their preparation
CA2531097C (en) Process for preparing formulations of lipid-regulating drugs
TR2021002339A2 (tr) Sefdi̇ni̇r i̇çeren fi̇lm kapli tablet
US20060177512A1 (en) Process for preparing formulations of lipid-regulating drugs
MXPA00006574A (en) Method and composition of an oral preparation of itraconazole

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20060410